{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:15:38Z","timestamp":1795032938510,"version":"4.10.2"},"reference-count":18,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acute myeloid leukemia (AML) patient outcomes remain heterogeneous, and new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B-lymphocyte precursors, which increase in number in hematologic diseases. The prognostic impact of the presence of detectable HGs on the leukemia-free survival (LFS) and overall survival of 120 consecutive patients with AML in first complete remission was investigated by flow cytometry. Patients who had HG levels more than 0.01% had a significantly better median LFS (29.2 vs 11.7 months; P = .001) and overall survival (not reached vs 23.5 months; P = .011). According to Cox analysis, an HG level more than 0.01% was an independent predictor of LFS (hazard ratio = 0.5; 95% confidence interval, 0.28-0.90, P &lt; .03) when age, leukocytosis, the number of chemotherapy cycles, and the standardized cytogenetic and molecular risk subgroups were controlled for. These results indicate that HG analysis may help to define the risk of relapse in AML patients.<\/jats:p>","DOI":"10.1182\/blood-2010-07-295378","type":"journal-article","created":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T01:19:45Z","timestamp":1289870385000},"page":"1315-1318","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Hematogones: a new prognostic factor for acute myeloblastic leukemia"],"prefix":"10.1182","volume":"117","author":[{"given":"Sylvain P.","family":"Chantepie","sequence":"first","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire, Caen, France;"},{"name":"Universit\u00e9 de Caen, Basse-Normandie, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Sala\u00fcn","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie, Centre Hospitalier Universitaire, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Parienti","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Caen, Basse-Normandie, France;"},{"name":"D\u00e9partement de Biostatistiques et de Recherche Clinique, Centre Hospitalier Universitaire, Caen, France;"},{"name":"Inserm, U 707, Paris, France;"},{"name":"Universit\u00e9 Pierre et Marie Curie, Paris 6, UMR-5 707, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Truquet","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matologie, Centre Hospitalier Universitaire, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Cheze","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Vilque","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Fran\u00e7ois Baclesse, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumedaly","family":"Reman","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2019111809431635800_B1","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"issue":"12","key":"2019111809431635800_B2","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood.V96.12.3948","article-title":"Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.","volume":"96","author":"Venditti","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111809431635800_B3","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood.V98.6.1746","article-title":"Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.","volume":"98","author":"San Miguel","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111809431635800_B4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","article-title":"Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.","volume":"101","author":"Kern","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111809431635800_B5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.leu.2404032","article-title":"Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia.","volume":"20","author":"Behl","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"2019111809431635800_B6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/ajcp\/79.3.277","article-title":"Terminal deoxynucleotidyl transferase (TdT)-positive cells in bone marrow in the absence of hematologic malignancy.","volume":"79","author":"Muehleck","year":"1983","journal-title":"Am J Clin Pathol"},{"key":"2019111809431635800_B7","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/ajcp\/7.5.436","article-title":"Hematological observations on bone marrow obtained by sternal puncture.","volume":"7","author":"Vogel","year":"1937","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2019111809431635800_B8","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood.V98.8.2498","article-title":"Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry.","volume":"98","author":"McKenna","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2019111809431635800_B9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.leu.2401279","article-title":"Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.","volume":"13","author":"Lucio","year":"1999","journal-title":"Leukemia"},{"issue":"8","key":"2019111809431635800_B10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/sj.leu.2400732","article-title":"Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.","volume":"11","author":"Dworzak","year":"1997","journal-title":"Leukemia"},{"issue":"24","key":"2019111809431635800_B11","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111809431635800_B12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111809431635800_B13","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2009.23.2652","article-title":"Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.","volume":"28","author":"Pautas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111809431635800_B14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/cncr.24943","article-title":"Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.","volume":"116","author":"Thomas","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"2019111809431635800_B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.leukres.2005.05.019","article-title":"Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.","volume":"30","author":"Ribeiro","year":"2006","journal-title":"Leuk Res"},{"issue":"9","key":"2019111809431635800_B16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.exphem.2004.06.001","article-title":"Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD\/SCID mouse.","volume":"32","author":"Shen","year":"2004","journal-title":"Exp Hematol"},{"issue":"10","key":"2019111809431635800_B17","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1080\/10428190701817274","article-title":"Hematogones in acute leukemia during and after therapy.","volume":"49","author":"Babusikova","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111809431635800_B18","first-page":"646","article-title":"Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.","volume":"88","author":"Kern","year":"2003","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/4\/1315\/1341444\/zh800411001315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/117\/4\/1315\/1341444\/zh800411001315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:37:31Z","timestamp":1574073451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/117\/4\/1315\/28579\/Hematogones-a-new-prognostic-factor-for-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-07-295378","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]}}}